US hospital sales of Novo Nordisk's hemophilia drug dropped in December
In December, Novo Nordisk's hemophilia treatment Novoseven sold less to US hospitals, shows data collected by Symphony Health Solutions.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Hospitals sales from Novo Nordisk's hemophilia drug Novoseven dropped 4.3 percent in December when calculated over a four-month period and compared with a similar period leading up to November, which data from Symphony Health Solutions shows, according to Bloomberg News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo ceases payments to US politicians
For subscribers
.jpg&w=384&q=75)
